Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $2.1 million.

  • Ultragenyx Pharmaceutical's Receivables - Other rose 1666.67% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 1666.67%. This contributed to the annual value of $1.8 million for FY2024, which is 6363.64% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Receivables - Other of $2.1 million as of Q3 2025, which was up 1666.67% from $900000.0 recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Receivables - Other peaked at $16.0 million during Q4 2021, and registered a low of $200000.0 during Q1 2024.
  • In the last 5 years, Ultragenyx Pharmaceutical's Receivables - Other had a median value of $2.4 million in 2024 and averaged $4.1 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Receivables - Other crashed by 9842.52% in 2024 and then skyrocketed by 110000.0% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Receivables - Other stood at $16.0 million in 2021, then tumbled by 60.0% to $6.4 million in 2022, then plummeted by 82.81% to $1.1 million in 2023, then skyrocketed by 63.64% to $1.8 million in 2024, then grew by 16.67% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $900000.0 for Q2 2025, and $2.4 million during Q1 2025.